GMAB
Genmab A/S is a Danish biotech company focused on oncology and cancer therapies, developing monoclonal antibodies and antibody-based drug conjugates for commercial and late-stage programs. The excerpt does not specify individual lead program names or approved products by name, though it references multiple marketed products and product candidates subject to competition from biosimilars and other cancer therapies. Genmab is integrating artificial intelligence and computational approaches into its drug discovery platform for antibody development and precision medicine applications.
Pipeline
Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups.
Anti-VEGF-A monoclonal antibody (Avastin) that inhibits tumor angiogenesis. Approved for colorectal, ovarian, breast, glioblastoma, and other solid tumors.
Alkylating chemotherapy that forms DNA crosslinks. Backbone in lymphoma (R-CHOP), breast cancer, and as conditioning regimen for stem cell transplant.
Taxane chemotherapy that stabilizes microtubules and arrests mitosis. Used in breast, prostate, NSCLC, head and neck, and gastric cancers.
Anthracycline chemotherapy that intercalates DNA and inhibits topoisomerase II. Backbone agent in breast cancer, lymphoma, leukemia, and sarcoma regimens.
Subcutaneous CD3xCD20 bispecific antibody (Epkinly) that redirects T cells to lyse CD20+ B-cell lymphomas. Approved for relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Pyrimidine nucleoside analog chemotherapy that incorporates into DNA and inhibits ribonucleotide reductase. First-line in pancreatic cancer; used in lung, breast, and bladder cancers.
Oral immunomodulatory drug (Revlimid) that recruits IKZF1/IKZF3 to cereblon for degradation. Standard in multiple myeloma, MDS, and follicular lymphoma.
Glycoengineered Type II anti-CD20 monoclonal antibody (Gazyva) with enhanced ADCC. Approved in chronic lymphocytic leukemia and follicular lymphoma.
Third-generation platinum chemotherapy that forms DNA adducts. Backbone in colorectal cancer (FOLFOX) and other GI malignancies.
Taxane chemotherapy that binds β-tubulin and prevents microtubule depolymerization, causing mitotic arrest. Used in breast, ovarian, lung, and other cancers.
Anti-PD-1 monoclonal antibody (Keytruda) that blocks the PD-1 checkpoint, restoring anti-tumor immune response. FDA-approved across many cancers including NSCLC, melanoma, and gastroesophageal cancer.
Oral synthetic corticosteroid used as anti-inflammatory and immunosuppressant. Backbone in lymphoma regimens (R-CHOP, BEACOPP) and supportive care.
Rinatabart sesutecan (Rina-S, Genmab/ProfoundBio): anti-FRα antibody conjugated to a topoisomerase I inhibitor payload. Phase 3 in platinum-resistant ovarian cancer.
Chimeric anti-CD20 monoclonal antibody (Rituxan) that depletes B cells via ADCC, CDC, and apoptosis. Foundational in B-cell lymphomas, CLL, rheumatoid arthritis, and ANCA vasculitis.
Topoisomerase I inhibitor chemotherapy used in small cell lung cancer, ovarian cancer, and cervical cancer.
Vinca alkaloid chemotherapy that inhibits microtubule polymerization, arresting mitosis. Used in lymphomas (R-CHOP), leukemias, and pediatric cancers.
5-fluorouracil. Pyrimidine analog chemotherapy that inhibits thymidylate synthase. Backbone in colorectal cancer regimens (FOLFOX, FOLFIRI).
Platinum-based chemotherapy that forms DNA crosslinks, inducing apoptosis in cancer cells. Standard of care across many solid tumors including NSCLC, ovarian, breast, bladder, and biliary cancers.
Platinum-based chemotherapy that forms DNA crosslinks. Foundational cytotoxic agent used across testicular, bladder, ovarian, head and neck, and lung cancers.
Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity.
Multi-targeted antifolate chemotherapy used in non-squamous NSCLC and mesothelioma, typically combined with platinum agents.
Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways.
Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecule, MMAE, is an anti-mitotic agent covalently attached to the antibody via a cleavable linker.
R-CHOP regimen: chemoimmunotherapy combination used as first-line in diffuse large B-cell lymphoma.
Oral selective BCL-2 inhibitor (Venclexta) that restores apoptosis in cancer cells. Approved for chronic lymphocytic leukemia, acute myeloid leukemia, and small lymphocytic lymphoma.